Compare RETO & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RETO | CMMB |
|---|---|---|
| Founded | 1999 | 2004 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6M | 11.2M |
| IPO Year | 2016 | 2023 |
| Metric | RETO | CMMB |
|---|---|---|
| Price | $0.63 | $1.88 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | ★ 2.1M | 36.3K |
| Earning Date | 05-05-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $43.50 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.48 | $0.87 |
| 52 Week High | $4.66 | $3.86 |
| Indicator | RETO | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 43.00 | 65.32 |
| Support Level | $0.54 | $1.44 |
| Resistance Level | $1.23 | $2.24 |
| Average True Range (ATR) | 0.13 | 0.13 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 17.59 | 86.00 |
ReTo Eco-Solutions Inc is a manufacturer and distributor of eco-friendly construction materials and fly ash, as well as equipment used to produce these eco-friendly construction materials. The company engaged in providing consultation, design, project implementation, and construction of urban ecological environments for capturing, controlling, and reusing rainwater. It operates through two segments, namely Machinery and Equipment sales, and Technology Consulting and other services. The company earns its revenue from the Machinery and Equipment sales segment. Geographically, it derives a majority of its revenue from China.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.